Calcionics Corporation

Based in Bellevue, Washington, Calcionics Corporation is a private company currently raising funds to complete pre-clinical studies and launch clinical trials investigating the safety and utility of its lead product candidate, CALC-100, a bioengineered peptide (fragment) of osteopontin, a naturally occurring anti-calcific protein. Prior animal work in co-founder Dr. Cecilia Giachelli’s laboratory at the University of Washington demonstrated osteopontin’s ability to prevent further calcification and to remove existing calcification from the vasculature and from implanted devices such as bioprosthetic heart valve tissue.